POLYMATERIA
15.6.2021 09:02:06 CEST | Business Wire | Press release
Polymateria, the London-based British tech company that last year produced the world’s first fully recyclable and biodegradable plastic, was selected among hundreds of candidates as one of the World Economic Forum’s “Technology Pioneers”. Polymateria came through Imperial College London’s incubator system and counts a diverse portfolio of customers and partners from Indorama Ventures, to Hollywood Actress Robin Wright, purposeful auto racing Extreme E, Rolling Loud Festivals, DAZN Sports TV network and the Indian Government.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005173/en/
The World Economic Forum’s Technology Pioneers are early to growth-stage companies from around the world that are involved in the use of new technologies and innovation that are poised to have a significant impact on business and society.
With their selection as Technology Pioneer, CEO Niall Dunne of Polymateria will be invited to participate at World Economic Forum activities, events and discussions throughout the year. Polymateria will also contribute to Forum initiatives over the next two years, working with global leaders to help address key industry and societal issues.
“We’re excited to welcome Polymateria to our 2021 cohort of Technology Pioneers,” says Susan Nesbitt, Head of the Global Innovators Community, World Economic Forum. “Polymateria and its fellow pioneers are developing technologies that can help society solve some of its most pressing issues. We look forward to their contribution to the World Economic Forum in its commitment to improving the state of the world.”
“It’s great to be acknowledged as a tech pioneer by the World Economic Forum”, said Polymateria’s CEO, Niall Dunne. “Since we were founded we’ve been obsessed with the scientific credibility and scale needed to solve the fugitive plastic crisis. This obsession has yielded a number of science based break throughs supported by & validated through new world leading standards specifically for the materials that are most likely to wind up in nature. It’s also clear that the ultimate beach head for innovation in this area is working with the next generation of consumers to empower them to champion the change needed from industry and other stakeholders and this will be our top priority in working within the WEF community.”
For the first time in the community’s history, over 30% of the cohort are led by women. The firms also come from regions all around the world, extending their community far beyond Silicon Valley. This year’s cohort includes start-ups from 26 countries, with UAE, El Salvador, Ethiopia and Zimbabwe represented for the first time.
The diversity of these companies extends to their innovations as well. 2021 Tech Pioneer firms are shaping the future by advancing technologies such as AI, IoT, robotics, blockchain, biotechnology and many more. The full list of Technology Pioneers can be found here .
Technology Pioneers have been selected based on the community’s selection criteria, which includes innovation, impact and leadership as well as the company’s relevance with the World Economic Forum’s Platforms .
All info on this year’s Technology Pioneers can be found here: http://wef.ch/techpioneers21
More information on past winners, information on the community and the application link can be found here .
About Polymateria :
Polymateria’s mission is to advance science to help nature deal with the plastic pollution crisis. Born from, and now based at, Imperial College London, they are the first company in the world to prove scientifically that you can take the most likely sources of fugitive or littered plastics and return them to nature without creating microplastics, harming the natural environment or interfering with recycling streams at scale.
The British Standards Institutions’s new BSI PAS 9017 standard ensures claims of biodegradability in the open environment can be properly verified for the first time according to independent pass/fail criteria. The Standard and Polymateria’s technology were recently featured in National Geographic magazine: https://www.nationalgeographic.co.uk/environment-and-conservation/2020/11/new-self-destructing-plastic-has-helped-define-a-new-british
Polymateria has partnership with some of the biggest technical partners in the world such as Clariant (now Avient, see https://www.clariant.com/en/Corporate/News/2019/10/Clariant-and-Polymateria-launch-partnership-to-bring-new-Biotransformation-technology-to-market-in-S ) and Indorama Ventures for non-woven applications (see https://www.innovationintextiles.com/indorama-companies-prepare-for-biotransformation/ ). Additionally the UK Govt included them as part of new trade with India (https://www.gov.uk/government/news/prime-minister-announces-1-billion-of-new-uk-india-trade ).
In its most recent collaboration, Polymateria will be providing Extreme E, an all-electric off-road racing series, with plastic cups and flexible film that in the unlikely event of escaping into the natural environment will safely and quickly biodegrade leaving no toxins and microplastics behind: https://www.extreme-e.com/en/news/214_Extreme-E-joins-forces-with-Polymateria-to-tackle-global-plastic-pollution.html
Pour Les Femmes, the ethical brand founded by actor/activitist Robin Wright and designer Karen Fowler, is the first apparel brand to introduce Polyamteria’s technology into its packaging: https://pourlesfemmes.com/blogs/pillowtalk/whats-the-future-of-plastic-waste-robin-wright-niall-dunne
The company is proud to be a founding signatory of HRH The Prince of Wales’ Terra Carta (Earth Charter) established under the Sustainable Markets Initiative.
About World Economic Forum :
The World Economic Forum, committed to improving the state of the world, is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business and other leaders of society to shape global, regional and industry agendas. (www.weforum.org ).
About the Technology Pioneers:
The World Economic Forum believes that innovation is critical to the future well-being of society and to driving economic growth. Launched in 2000, the Technology Pioneer community is composed of early to growth-stage companies from around the world that are involved in the design, development and deployment of new technologies and innovations, and are poised to have a significant impact on business and society.
The World Economic Forum provides the Technology Pioneers community with a platform to engage with the public- and private-sector leaders and to contribute new solutions to overcome the current crisis and build future resiliency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005173/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
